anti-GPRC5D/anti-CD19 CAR T cells

{
  "id": "MLC-T-ONC-010720",
  "term": "anti-GPRC5D/anti-CD19 CAR T cells",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of T lymphocytes engineered to express chimeric antigen receptor(s) (CARs) targeting the human tumor-associated antigens (TAAs) G-protein coupled receptor family C group 5 member D (GPRC5D) and CD19, with potential immunostimulating and antineoplastic activities. Upon administration, anti-GPRC5D/anti-CD19 CAR T cells specifically and simultaneously target and bind to tumor cells expressing GPRC5D and/or CD19. This induces selective toxicity in tumor cells that express GPRC5D and/or CD19. GPRC5D is overexpressed in certain malignancies, such as multiple myeloma, while minimally expressed in normal, healthy cells. It plays a key role in tumor cell proliferation. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies.",
  "synonyms": [
    "GPRC5D-CD19 CAR T cells",
    "anti-CD19/anti-GPRC5D CAR T cells",
    "anti-GPRC5D-CD19-CAR-T cells",
    "anti-GPRC5D/CD19 CAR T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-gprc5d-anti-cd19-car-t-cells/"
}